Richard E. Champlin

TL;DR: The data suggest that efforts to improve outcomes in adult CB transplant recipients should be aimed at optimizing T-cell immune recovery, and strategies that improve the engraftment of lymphoid precursors, protect the thymus during pretransplant conditioning, and/or augment the recovery of thymopoiesis may improve outcomes after CBT.

TL;DR: In vitro-generated DCs can be effectively used as antigen-presenting cells for the ex vivo expansion of antileukemic T cells, suggesting that cytokine-driven in vitro differentiation of CML cells results in generation of DCs with potent T-cell stimulatory function.

TL;DR: Survival in CML has significantly improved since 2001, particularly so in CP-AML and AP-CML, and Imatinib therapy minimized the impact of known prognostic factors and Sokal risk in CP -CML and accentuated theimpact of age in AP- and BP-C ML.

TL;DR: Letermovir was effective in reducing the incidence of CMV infection in recipients of allogeneic hematopoietic-cell transplants, with no indication of hematologic toxicity or nephrotoxicity.

TL;DR: Community respiratory viruses (CRVs) have been recognized as a potential cause of pneumonia and death among hematopoietic stem cell transplantation (HSCT) recipients and patients with hematologic malignancies and HSCT recipients should be considered for antiviral therapy of proven efficacy to reduce the risk of tuberculosis and death.